{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 7887, "pageSize": 30, "pageCount": 10666, "rows": [ { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "traction", "function": "show_traction", "notes": "The slide presents three line charts (A, B, C) comparing PBS, IMI (Imipenem), and two doses of EBO (EBO25, EBO50) over 4 weeks.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/16", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-16", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/17", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-17", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "problem_statement", "function": "frame_problem", "notes": "Includes a map showing global distribution and a specific callout for US endemicity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/18", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-18", "loopMatches": [ { "to": 21, "from": 18, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "ca1bff99-ab8b-4217-9926-524e39a8b895", "evidence": "The document presents the potential benefits of AN2 Therapeutics' pipeline candidates in reducing mortality and improving patient outcomes.", "position": 0, "objective": "What is the cost of inaction in addressing these diseases?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 19, "from": 18, "beatId": "ed4f0423-09b8-4627-93a7-56bf94f26399", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document presents the problem statement for melioidosis and Chagas disease.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a central hub-and-spoke style diagram to connect funding sources with market potential.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/19", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-19", "loopMatches": [ { "to": 21, "from": 18, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "ca1bff99-ab8b-4217-9926-524e39a8b895", "evidence": "The document presents the potential benefits of AN2 Therapeutics' pipeline candidates in reducing mortality and improving patient outcomes.", "position": 0, "objective": "What is the cost of inaction in addressing these diseases?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 19, "from": 18, "beatId": "ed4f0423-09b8-4627-93a7-56bf94f26399", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document presents the problem statement for melioidosis and Chagas disease.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "traction", "function": "show_traction", "notes": "The chart shows Log10 CFU counts in lungs for various treatment groups compared to untreated control.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/20", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-20", "loopMatches": [ { "to": 21, "from": 18, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "ca1bff99-ab8b-4217-9926-524e39a8b895", "evidence": "The document presents the potential benefits of AN2 Therapeutics' pipeline candidates in reducing mortality and improving patient outcomes.", "position": 0, "objective": "What is the cost of inaction in addressing these diseases?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "timeline", "function": "plan_implementation", "notes": "The slide uses a dual-track timeline approach to show the progression from observational data collection to clinical trial phases.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/21", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-21", "loopMatches": [ { "to": 21, "from": 18, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "ca1bff99-ab8b-4217-9926-524e39a8b895", "evidence": "The document presents the potential benefits of AN2 Therapeutics' pipeline candidates in reducing mortality and improving patient outcomes.", "position": 0, "objective": "What is the cost of inaction in addressing these diseases?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/22", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-22", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "problem_statement", "function": "frame_problem", "notes": "Includes a disease progression timeline diagram on the right.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/23", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-23", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a hub-and-spoke diagram to break down global prevalence numbers.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/24", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-24", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a dot map to visualize geographic distribution of infections.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/25", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "solution", "function": "present_solution", "notes": "Includes chemical structure of the drug candidate.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/26", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "traction", "function": "show_traction", "notes": "The chart demonstrates superior efficacy of the lead compound over existing treatments (Benznidazole and E1224) in a model that mirrors human clinical outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/27", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "competitive_analysis", "function": "compare_peers", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/28", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "timeline", "function": "plan_implementation", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/29", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-29", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/30", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-30", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a hub-and-spoke diagram to connect Boron to various therapeutic areas, specifically focusing on oncology applications.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/31", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a hub-and-spoke diagram to connect the central Boron element to four therapeutic areas, then maps those to two specific drug development programs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/32", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/33", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/34", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/35", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-35", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-8566-7247-8a65-bb40d287c138", "docSlug": "3a5ef691e659aba2296672e3bbfa035c", "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/36", "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138", "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-36", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-85fc-775a-8753-16d843ecec69", "docSlug": "7fa2b1dd15815365fa1a607d70c61211", "documentTitle": "Hagerty | Investor Presentation Deck | 22 slides", "authorId": "hagerty", "authorName": "Hagerty", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/ikvIs-HREbu9ehd4RuuO-w93l3-K49d4eq1gAF_Phec/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83ZmEyYjFkZDE1ODE1MzY1ZmExYTYwN2Q3MGM2MTIxMS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-85fc-775a-8753-16d843ecec69/1", "deckHref": "/decks/019de077-85fc-775a-8753-16d843ecec69", "deckAnchorHref": "/decks/019de077-85fc-775a-8753-16d843ecec69#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/nuOCAN5VtD8FGs59aDbjiJE6nDTDr4-JE-fYlmExLn8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83ZmEyYjFkZDE1ODE1MzY1ZmExYTYwN2Q3MGM2MTIxMS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/S3e9CKGnUJHy5eAtLVOEeMaYbBhYYJ6Pl6HYNANroiw/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83ZmEyYjFkZDE1ODE1MzY1ZmExYTYwN2Q3MGM2MTIxMS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/9Aw3egaX0rkFc74i7djmVUktp2k3Rsac6zJpGAWa-FI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83ZmEyYjFkZDE1ODE1MzY1ZmExYTYwN2Q3MGM2MTIxMS9wMDAxLnBuZw" }, { "docId": "019de077-85fc-775a-8753-16d843ecec69", "docSlug": "7fa2b1dd15815365fa1a607d70c61211", "documentTitle": "Hagerty | Investor Presentation Deck | 22 slides", "authorId": "hagerty", "authorName": "Hagerty", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-85fc-775a-8753-16d843ecec69/2", "deckHref": "/decks/019de077-85fc-775a-8753-16d843ecec69", "deckAnchorHref": "/decks/019de077-85fc-775a-8753-16d843ecec69#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-85fc-775a-8753-16d843ecec69", "docSlug": "7fa2b1dd15815365fa1a607d70c61211", "documentTitle": "Hagerty | Investor Presentation Deck | 22 slides", "authorId": "hagerty", "authorName": "Hagerty", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a split layout with a financial performance table on the left and a lifestyle image on the right.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-85fc-775a-8753-16d843ecec69/3", "deckHref": "/decks/019de077-85fc-775a-8753-16d843ecec69", "deckAnchorHref": "/decks/019de077-85fc-775a-8753-16d843ecec69#slide-3", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 3, "beatId": "0ba84432-6e5b-4ecd-80fb-514c47e9f16b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Slides 3-5 discuss traction and key messages, implying a problem or opportunity", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-85fc-775a-8753-16d843ecec69", "docSlug": "7fa2b1dd15815365fa1a607d70c61211", "documentTitle": "Hagerty | Investor Presentation Deck | 22 slides", "authorId": "hagerty", "authorName": "Hagerty", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a split-screen layout with a thematic car image on the left and financial highlights on the right.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-85fc-775a-8753-16d843ecec69/4", "deckHref": "/decks/019de077-85fc-775a-8753-16d843ecec69", "deckAnchorHref": "/decks/019de077-85fc-775a-8753-16d843ecec69#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 3, "beatId": "0ba84432-6e5b-4ecd-80fb-514c47e9f16b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Slides 3-5 discuss traction and key messages, implying a problem or opportunity", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-85fc-775a-8753-16d843ecec69", "docSlug": "7fa2b1dd15815365fa1a607d70c61211", "documentTitle": "Hagerty | Investor Presentation Deck | 22 slides", "authorId": "hagerty", "authorName": "Hagerty", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "key_messages", "function": "prioritize", "notes": "The slide uses a split layout with a large atmospheric photo of a car event on the right.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-85fc-775a-8753-16d843ecec69/5", "deckHref": "/decks/019de077-85fc-775a-8753-16d843ecec69", "deckAnchorHref": "/decks/019de077-85fc-775a-8753-16d843ecec69#slide-5", "loopMatches": [ { "to": 11, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "8e13d353-b8d6-483d-a1b2-e33ac5f34bc2", "evidence": "Slides 5 and 11 discuss growth and margin expansion, implying a cost of inaction", "position": 0, "objective": "Highlight the importance of investing in growth", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 5, "from": 3, "beatId": "0ba84432-6e5b-4ecd-80fb-514c47e9f16b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Slides 3-5 discuss traction and key messages, implying a problem or opportunity", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-85fc-775a-8753-16d843ecec69", "docSlug": "7fa2b1dd15815365fa1a607d70c61211", "documentTitle": "Hagerty | Investor Presentation Deck | 22 slides", "authorId": "hagerty", "authorName": "Hagerty", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "use_of_funds", "function": "plan_implementation", "notes": "The slide highlights the transition from legacy systems to a modern platform, acknowledging short-term cost increases due to redundancy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-85fc-775a-8753-16d843ecec69/6", "deckHref": "/decks/019de077-85fc-775a-8753-16d843ecec69", "deckAnchorHref": "/decks/019de077-85fc-775a-8753-16d843ecec69#slide-6", "loopMatches": [ { "to": 11, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "8e13d353-b8d6-483d-a1b2-e33ac5f34bc2", "evidence": "Slides 5 and 11 discuss growth and margin expansion, implying a cost of inaction", "position": 0, "objective": "Highlight the importance of investing in growth", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 8, "from": 6, "beatId": "46cb5271-50b2-4855-bf0c-ade0919562f1", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slides 6-8 discuss technology spend and strong double-digit gains, implying a solution", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-85fc-775a-8753-16d843ecec69", "docSlug": "7fa2b1dd15815365fa1a607d70c61211", "documentTitle": "Hagerty | Investor Presentation Deck | 22 slides", "authorId": "hagerty", "authorName": "Hagerty", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "traction", "function": "show_traction", "notes": "Includes footnotes regarding hurricane impact on loss ratio and non-GAAP measures.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-85fc-775a-8753-16d843ecec69/7", "deckHref": "/decks/019de077-85fc-775a-8753-16d843ecec69", "deckAnchorHref": "/decks/019de077-85fc-775a-8753-16d843ecec69#slide-7", "loopMatches": [ { "to": 11, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "8e13d353-b8d6-483d-a1b2-e33ac5f34bc2", "evidence": "Slides 5 and 11 discuss growth and margin expansion, implying a cost of inaction", "position": 0, "objective": "Highlight the importance of investing in growth", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 8, "from": 6, "beatId": "46cb5271-50b2-4855-bf0c-ade0919562f1", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slides 6-8 discuss technology spend and strong double-digit gains, implying a solution", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 10, "from": 7, "beatId": "88d612b7-ee5f-41e4-946d-b314bdcf36a2", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "Slides 7-10 discuss financial highlights and earnings analysis", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-85fc-775a-8753-16d843ecec69", "docSlug": "7fa2b1dd15815365fa1a607d70c61211", "documentTitle": "Hagerty | Investor Presentation Deck | 22 slides", "authorId": "hagerty", "authorName": "Hagerty", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "traction", "function": "show_traction", "notes": "The slide uses stacked bar charts to show revenue composition and growth rates for three distinct business segments.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-85fc-775a-8753-16d843ecec69/8", "deckHref": "/decks/019de077-85fc-775a-8753-16d843ecec69", "deckAnchorHref": "/decks/019de077-85fc-775a-8753-16d843ecec69#slide-8", "loopMatches": [ { "to": 11, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "8e13d353-b8d6-483d-a1b2-e33ac5f34bc2", "evidence": "Slides 5 and 11 discuss growth and margin expansion, implying a cost of inaction", "position": 0, "objective": "Highlight the importance of investing in growth", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 8, "from": 6, "beatId": "46cb5271-50b2-4855-bf0c-ade0919562f1", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slides 6-8 discuss technology spend and strong double-digit gains, implying a solution", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 10, "from": 7, "beatId": "88d612b7-ee5f-41e4-946d-b314bdcf36a2", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "Slides 7-10 discuss financial highlights and earnings analysis", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-85fc-775a-8753-16d843ecec69", "docSlug": "7fa2b1dd15815365fa1a607d70c61211", "documentTitle": "Hagerty | Investor Presentation Deck | 22 slides", "authorId": "hagerty", "authorName": "Hagerty", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2025-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide uses bar charts to visualize financial performance over three years.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de077-85fc-775a-8753-16d843ecec69/9", "deckHref": "/decks/019de077-85fc-775a-8753-16d843ecec69", "deckAnchorHref": "/decks/019de077-85fc-775a-8753-16d843ecec69#slide-9", "loopMatches": [ { "to": 11, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "8e13d353-b8d6-483d-a1b2-e33ac5f34bc2", "evidence": "Slides 5 and 11 discuss growth and margin expansion, implying a cost of inaction", "position": 0, "objective": "Highlight the importance of investing in growth", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 10, "from": 7, "beatId": "88d612b7-ee5f-41e4-946d-b314bdcf36a2", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "Slides 7-10 discuss financial highlights and earnings analysis", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }